The University of Pennsylvania Cancer Center is the largest and oldest institute of the University of Pennsylvania. Its mission is to facilitate multi-disciplinary, interdepartmental cancer research, education and patient care. Its mission is to facilitate multi-disciplinary, interdepartmental cancer research, education and Glick, MD, has directed the Cancer Center for 14 years. The Cancer Center's three Divisions (Fundamental Research, Clinical Research, and Population Science and Cancer Control) are comprised of inter-disciplinary Research Programs in: Immunobiology, Tumor Biology, Virology, Clinical Investigations, Melanoma, Pediatric Oncology, Radiation Biology, Gene Therapy in Cancer, Stem Cell Biology and Therapeutics, Neuro-Oncology, Breast Cancer, and Behavioral Sciences and Health Services Research Programs as well as a Developing Chemoprevention Program. This application includes 16 Shared Resources. The Flow Cytometry and Cell Sorting Facility, Nucleic Acid Facility, Melanoma Core, Biostatistics Unit and Clinical Research Unit are among the oldest NCI-funded cores. A wide range of research seminars and interdisciplinary laboratory space are used to facilitate member interaction and collaboration. Developmental Funds are critical to supporting faculty recruitment, innovative pilot projects that have the potential for peer-reviewed funding, translational research initiatives and Shared Resources. The development and expansion of Research Programs and Shared Resources, along with the recruitment of new faculty and acquisition of additional research space have all contributed to helping the Cancer Center reach its current level of excellence. A comprehensive, interactive strategic planning process has been instrumental in identifying future directions in cancer research, Research Programs and Shared Resources and allocation of resources. The Cancer Center continues to meet Comprehensiveness guidelines and was last fully approved for the maximum five-year period in 1995. Cancer Center members have $99.2 million in research and training in total costs (direct and indirect), of which $91 million is peer-reviewed and $35.4 million is from the National Cancer Institute.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016520-26
Application #
6328866
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ciolino, Henry P
Project Start
1978-12-01
Project End
2004-11-30
Budget Start
2000-12-01
Budget End
2001-11-30
Support Year
26
Fiscal Year
2001
Total Cost
$5,071,158
Indirect Cost
Name
University of Pennsylvania
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Liu, Wei; Krump, Nathan A; MacDonald, Margo et al. (2018) Merkel Cell Polyomavirus Infection of Animal Dermal Fibroblasts. J Virol 92:
Schapira, Marilyn M; Barlow, William E; Conant, Emily F et al. (2018) Communication Practices of Mammography Facilities and Timely Follow-up of a Screening Mammogram with a BI-RADS 0 Assessment. Acad Radiol 25:1118-1127
Morrison, Alexander H; Byrne, Katelyn T; Vonderheide, Robert H (2018) Immunotherapy and Prevention of Pancreatic Cancer. Trends Cancer 4:418-428
Yan, Lesan; Amirshaghaghi, Ahmad; Huang, Dennis et al. (2018) Protoporphyrin IX (PpIX)-Coated Superparamagnetic Iron Oxide Nanoparticle (SPION) Nanoclusters for Magnetic Resonance Imaging and Photodynamic Therapy. Adv Funct Mater 28:
Ojha, Rani; Leli, Nektaria M; Onorati, Angelique et al. (2018) ER translocation of the MAPK pathway drives therapy resistance in BRAF mutant melanoma. Cancer Discov :
Han, Joseph; Lachance, Catherine; Ricketts, M Daniel et al. (2018) The scaffolding protein JADE1 physically links the acetyltransferase subunit HBO1 with its histone H3-H4 substrate. J Biol Chem 293:4498-4509
Waxman, Adam J; Clasen, Suparna; Hwang, Wei-Ting et al. (2018) Carfilzomib-Associated Cardiovascular Adverse Events: A Systematic Review and Meta-analysis. JAMA Oncol 4:e174519
Gangadhar, Tara C; Savitch, Samantha L; Yee, Stephanie S et al. (2018) Feasibility of monitoring advanced melanoma patients using cell-free DNA from plasma. Pigment Cell Melanoma Res 31:73-81
Reshef, Ran; Ganetsky, Alex; Acosta, Edward P et al. (2018) Extended CCR5 Blockade for Graft-versus-Host Disease Prophylaxis Improves Outcomes of Reduced-Intensity Unrelated Donor Hematopoietic Cell Transplantation: A Phase II Clinical Trial. Biol Blood Marrow Transplant :
Lang, Fengchao; Sun, Zhiguo; Pei, Yonggang et al. (2018) Shugoshin 1 is dislocated by KSHV-encoded LANA inducing aneuploidy. PLoS Pathog 14:e1007253

Showing the most recent 10 out of 1047 publications